Efficacy of 5-FU or Oxaliplatin Monotherapy over Combination Therapy in Colorectal Cancer
Efficacy of 5-FU or Oxaliplatin Monotherapy over Combination Therapy in Colorectal Cancer作者机构：Research Genetic Cancer Centre Ltd. (R.G.C.C. Ltd.) Florina Greece
出 版 物：《Journal of Cancer Therapy》 (癌症治疗（英文）)
年 卷 期：2015年第6卷第4期
页 面：345-355页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：5-Fluorouracil Oxaliplatin FOLFOX Colon Cancer Stem Cells
摘 要：Recent clinical and research development supports the use of 5-fluorouracil in combination with oxaliplatin for the treatment of patients with advanced colorectal cancer (CRC). 5-Fluorouracil (5-FU), which is as an anti-metabolite, is a widely used cytostatic drug. Although the rate of response, quality of life and overall survival differs between CRC patients, the above combination remains a widely used chemotherapeutic regimen. In some cases, a cancer stem cell (CSC) population may resist the majority of chemotherapeutic models. This study investigated if monotherapy is more efficacious than 5-fluorouracil and oxaliplatin combined for the treatment of CRC, using a CRC cell line and a CSC-like line. Cell viability was evaluated by cellular-based assays, and quantitative polymerase chain reaction (q-PCR) assays were performed to assess the expression of specific genes (TYMS,?DNMT1,?NANOG, DHFR, SHMT1, ERCC1, DPYD) correlated with 5-FU and oxaliplatin resistance. We observed that 5-fluorouracil was more effective in both CRC and CSCs. This finding proved the hypothesis that, in some cases, monotherapy may be more successful in CRC treatment than a drug combination that may be cytotoxic and inflict adverse side effects.
维普期刊数据库